TCC1727 combination therapy for advanced solid tumors
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Immune system & allergy, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have an advanced or metastatic solid tumor that has worsened after standard treatment, or you cannot have standard treatment.
- You must have at least one measurable tumor that can be seen on scans.
- You must be able to swallow pills whole.
- You must have good organ function, such as adequate blood counts and liver/kidney function.
- You must agree to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.